ICON Public Limited (NASDAQ:ICLR) Shares Sold by Somerset Trust Co

Somerset Trust Co reduced its holdings in shares of ICON Public Limited (NASDAQ:ICLR) by 4.1% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,994 shares of the medical research company’s stock after selling 85 shares during the quarter. Somerset Trust Co’s holdings in ICON Public were worth $418,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. EverSource Wealth Advisors LLC grew its position in shares of ICON Public by 39.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 394 shares of the medical research company’s stock valued at $129,000 after buying an additional 111 shares during the last quarter. GAMMA Investing LLC boosted its stake in ICON Public by 64.0% in the fourth quarter. GAMMA Investing LLC now owns 433 shares of the medical research company’s stock valued at $91,000 after acquiring an additional 169 shares in the last quarter. Whittier Trust Co. of Nevada Inc. grew its holdings in shares of ICON Public by 23.1% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 511 shares of the medical research company’s stock worth $147,000 after purchasing an additional 96 shares during the last quarter. First Horizon Advisors Inc. increased its position in shares of ICON Public by 33.9% during the third quarter. First Horizon Advisors Inc. now owns 597 shares of the medical research company’s stock worth $172,000 after purchasing an additional 151 shares in the last quarter. Finally, Arkadios Wealth Advisors lifted its holdings in shares of ICON Public by 5.0% in the 3rd quarter. Arkadios Wealth Advisors now owns 1,293 shares of the medical research company’s stock valued at $371,000 after purchasing an additional 62 shares during the last quarter. Hedge funds and other institutional investors own 95.61% of the company’s stock.

ICON Public Price Performance

ICON Public stock opened at $198.11 on Friday. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. The firm’s 50-day simple moving average is $209.71 and its 200 day simple moving average is $268.23. ICON Public Limited has a 52 week low of $183.38 and a 52 week high of $347.72. The firm has a market capitalization of $16.34 billion, a PE ratio of 22.09, a P/E/G ratio of 1.59 and a beta of 1.20.

ICON Public (NASDAQ:ICLR) last announced its earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The company had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. During the same quarter last year, the company posted $3.10 EPS. ICON Public’s quarterly revenue was down 1.2% compared to the same quarter last year. On average, equities research analysts predict that ICON Public Limited will post 13.41 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on ICLR. William Blair restated an “outperform” rating on shares of ICON Public in a research note on Tuesday. TD Cowen lowered their target price on shares of ICON Public from $369.00 to $285.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Baird R W downgraded shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 24th. The Goldman Sachs Group lowered their price objective on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. Finally, Redburn Atlantic assumed coverage on shares of ICON Public in a report on Monday, October 14th. They issued a “neutral” rating and a $311.00 target price for the company. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $287.00.

ICON Public Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.